Aktienanalyse zu Biofrontera Inc (BFRI)BFRIBiofrontera Inc

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Biofrontera Inc is a good buy right now due to its recent positive momentum and potential for recovery. The stock is currently priced at $0.83, which is significantly below its 52-week high of $1.66, indicating a potential upside of 100% if it returns to that level. Additionally, the company has shown a gross margin of 79.92% in the most recent quarter, suggesting strong profitability potential as revenues increase. The main risk is the negative earnings per share (EPS) estimate of -0.33 for the upcoming quarter, which could impact investor sentiment.